Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28367193 | 0.89 | TAAR1 (0.54) | TAAR1PTGS1PTGS2MAOBIDO1 | |
| SCHEMBL8301476 | 0.85 | MEN1 (0.53) | TAAR1KCNH3MAPK1MEN1KMT2A | |
| SCHEMBL9358826 | 0.81 | CA2 (0.60) | TAAR1MAPK1MEN1KMT2AUSP2 | |
| SCHEMBL1965032 | 0.81 | IDO1 (0.50) | KCNH3MAOBIDO1AGXT | |
| SCHEMBL7438849 | 0.80 | TAAR1 (0.42) | TAAR1MAPK1MEN1KMT2AUSP2 | |
| SCHEMBL10792748 | 0.79 | KCNH2 (0.51) | TAAR1MAPK1MEN1KMT2AUSP2 | |
| SCHEMBL9439014 | 0.79 | MEN1 (0.42) | MAPK1MEN1KMT2AUSP2ALDH1A1 | |
| Ethylene Glycol SCHEMBL5570418 | 0.79 | IDO1 (0.48) | KCNH3MAOBIDO1AGXT | |
| SCHEMBL17986295 | 0.79 | TAAR1 (0.45) | TAAR1MAOBIDO1AGXTAOC3 | |
| SCHEMBL8097545 | 0.79 | TAAR1 (0.61) | TAAR1MAOBIDO1AGXTAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102477008-B | Method for synthesizing ezetimibe | UNIV SHENYANG PHARMACEUTICAL | 2014-05-21 | — | — | CN | claimed |
| CN-102477008-A | Synthesis method of ezetimibe | UNIV SHENYANG PHARMACEUTICAL | 2012-05-30 | — | — | CN | claimed |
| CN-102477008-B | Method for synthesizing ezetimibe | UNIV SHENYANG PHARMACEUTICAL | 2014-05-21 | — | — | CN | disclosed |
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| CN-102477008-A | Synthesis method of ezetimibe | UNIV SHENYANG PHARMACEUTICAL | 2012-05-30 | — | — | CN | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
| CN-1129599-C | Substituted benzothiazine/oxazine-2-amine derivatives, co-preparation method and application thereof | PF MEDICAMENT (FR) | 2003-12-03 | — | — | CN | disclosed |
| US-6531469-B1 | Treatment of myocardial ischemia, chronic stable angina, unstable angina and prinzmetal's angina attacks, silent cardiac ischemia, reinfarction, reocclusion and restenosis | PIERRE FABRE MEDICAMENT (FR) | 2003-03-11 | — | — | US | disclosed |
| EP-1144408-B1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PF MEDICAMENT (FR) | 2002-09-25 | — | — | EP | disclosed |
| CN-1344267-A | Substituted 1- (piperidin-4-yl) -3- (aryl) isothioureas, their preparation and their therapeutic use | PF MEDICAMENT (FR) | 2002-04-10 | — | — | CN | disclosed |
| EP-1144408-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043391-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
| US-4649160-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-03-10 | — | — | US | disclosed |
| EP-0041233-B1 | SUBSTITUTED PHENOXY-AMINOPROPANOL DERIVATIVES, INTERMEDIATES AND PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-15 | — | — | EP | disclosed |
| EP-0041233-A1 | Substituted phenoxy-aminopropanol derivatives, intermediates and processes for their production, and pharmaceutical preparations containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | TAAR1 608/4885KCNH3 670/4885MAPK1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.